Patents by Inventor Matthew J. Bernett

Matthew J. Bernett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6
    Publication number: 20240132584
    Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
    Type: Application
    Filed: July 5, 2023
    Publication date: April 25, 2024
    Inventors: Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11945880
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: April 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND GPC3
    Publication number: 20240034815
    Abstract: Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.
    Type: Application
    Filed: July 25, 2023
    Publication date: February 1, 2024
    Inventors: Alex Nisthal, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Matthew J. Bernett, Rajat Varma
  • LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
    Publication number: 20240025968
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a LAG-3 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: April 6, 2023
    Publication date: January 25, 2024
    Inventors: Matthew J. Bernett, John R. Desjarlais, Suzanne Schubbert
  • BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS
    Publication number: 20240026002
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Application
    Filed: August 18, 2023
    Publication date: January 25, 2024
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11859011
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: January 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and GPC3
    Patent number: 11859012
    Abstract: Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: January 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Alex Nisthal, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Matthew J. Bernett, Rajat Varma
  • TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15/IL-15RA AND NKG2D ANTIGEN BINDING DOMAINS
    Publication number: 20230340053
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL,-15R? Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
    Type: Application
    Filed: October 18, 2022
    Publication date: October 26, 2023
    Inventors: Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
  • OPTIMIZED ANTIBODIES THAT TARGET CD19
    Publication number: 20230340144
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: February 21, 2023
    Publication date: October 26, 2023
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • TIM-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND TIM-3 ANTIGEN BINDING DOMAINS
    Publication number: 20230331813
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: October 13, 2022
    Publication date: October 19, 2023
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
    Publication number: 20230279071
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a LAG-3 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: April 28, 2023
    Publication date: September 7, 2023
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20230272114
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: December 22, 2022
    Publication date: August 31, 2023
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Heterodimeric antibodies that bind CD3 and CLDN6
    Patent number: 11739144
    Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: August 29, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11673972
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: June 13, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Optimized antibodies that target CD19
    Patent number: 11618788
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: April 4, 2023
    Assignee: XENCOR, INC.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
    Patent number: 11618776
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: April 4, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 11566080
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: January 31, 2023
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • IL-7-FC-fusion proteins
    Patent number: 11512122
    Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 29, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
  • TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
    Patent number: 11505595
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: November 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20220348634
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 3, 2022
    Inventors: Gregory A. Lazar, Matthew J. Bernett